A report from Leerink predicted Thermo Fisher Scientific could launch such a system within the next year, potentially opening up the clinical mass spec market.
Bruker said it plans to use InVivo assets to explore antibody enrichment methods that could eliminate the need for culturing prior to MALDI-based microbial ID.
Bioyong will invest in test development as well as validation, regulatory approval, and commercialization in China and, possibly, other Asia-Pacific countries.
The company recently acquired intellectual property and personnel to drive development of PCR tests for applications including syndromic microbiology testing.
The test is designed to replace gel electrophoresis assays currently used for measuring M-proteins, biomarkers for plasma cell diseases such as multiple myeloma.